Most NLRP3-AID patients are highly responsive to IL-1–targeted therapies, especially on cutaneous, ocular, and articular features, and prevention of inflammatory amyloidosis (Booshehri and Hoffman, 2019). The gene discussed is NLRP3; the disease is AA amyloidosis.